MGTA News and Press, Magenta Therapeutics Inc. From 09/02/20

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnso...

– Magenta to present five abstracts showcasing data across clinical and pre-clinical pipeline, including mobilization and conditioning programs – – Phase I clinical trial results confirm that MGTA-145 demonstrates same-day mobilization and collection of highly func...

"The only sure rule in golf is he who has the fastest cart never has to play the bad lie. ” – Mickey Mantle Today, we take an in-depth look at a Busted IPO that recently retrenched and raised additional capital after abandoning a mid-stage trial. A full investment analysis f...

Magenta Therapeutics (NASDAQ: MGTA ) : Q2 GAAP EPS of -$0.48 beats by $0.06 . Cash, cash equivalents and marketable securities of $176.5M Press Release More news on: Magenta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

– Collaborations announced with AVROBIO and Beam Therapeutics to evaluate potential usage of MGTA-117 in conditioning patients in gene therapy and gene editing settings, respectively — – MGTA-145 to move into Phase 2 trials in autologous and allogeneic transplant i...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor conferences: BTIG Virtual Healthcar...

Francesca's (NASDAQ: FRAN )  +87%  on teaming up with Poq to develop mobile application. More news on: Francesca's Holdings Corporation, Venus Concept Inc., ION Geophysical Corporation, Stocks on the move, , Read more ...

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common s...

Shares of Magenta Therapeutics (NASDAQ: MGTA) are down by 16.6% as of 11:39 a.m. EDT on Thursday after the company announced the pricing of a public offering of common stock on Wednesday evening. Magenta's decision to issue new shares will dilute existing shareholders, which explains why the...

Magenta Therapeutics (NASDAQ: MGTA ) has priced its public offering of 7.5M common shares at $8.00/share, for expected gross proceeds of $60M. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, , Read more ...